key: cord-0263415-ztwemu74
authors: Yadav, Pragya D.; Sahay, Rima R; Sapkal, Gajanan; Nyayanit, Dimpal; Shete, Anita M.; Deshpande, Gururaj; Patil, Deepak Y.; Gupta, Nivedita; Kumar, Sanjay; Abraham, Priya; Panda, Samiran; Bhargava, Balram
title: Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152
date: 2021-08-01
journal: bioRxiv
DOI: 10.1101/2021.07.30.454511
sha: 65c415e6b31070c76b12aabc758baee1c006f43d
doc_id: 263415
cord_uid: ztwemu74

The recent emergence of the SARS-CoV-2 Variant of Concern, B.1.617.2 (Delta) variant and its high transmissibility has led to the second wave in India. BBV152, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in India, showed a 65.2% protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial. Subsequently, Delta has been further mutated to Delta AY.1, AY.2, and AY.3. Of these, AY.1 variant was first detected in India in April 2021 and subsequently from twenty other countries as well. Here, we have evaluated the IgG antibody titer and neutralizing potential of sera of COVID-19 naive individual’s full doses of BBV152 vaccine, COVID-19 recovered cases with full dose vaccines and breakthrough cases post-immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3. A reduction in neutralizing activity was observed with the COVID-19 naive individuals full vaccinated (1.3, 1.5, 1.9-fold), COVID-19 recovered cases with full BBV152 immunization (2.5, 3.5, 3.8-fold) and breakthrough cases post-immunization (1.9, 2.8, 3.5-fold) against Delta, Delta AY.1 and B.1.617.3 respectively compared to B.1 variant. A minor reduction was observed in the neutralizing antibody titer in COVID-19 recovered cases full BBV152 vaccinated and post immunized infected cases compared to COVID-19 naive vaccinated individuals. However, with the observed high titers, the sera of individuals belonging to all the aforementioned groups they would still neutralize the Delta, Delta AY.1 and B.1.617.3 variants effectively.

The recent emergence of the SARS-CoV-2 Variant of Concern, B.1.617.2 (Delta) variant and its high transmissibility has led to the second wave in India. BBV152, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in India, showed a 65.2% protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial. Subsequently, Delta has been further mutated to Delta AY.1, AY. 

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Delta variant (B.1.617.2), a variant of concern (VOC), was associated with the second wave in India during ORF7b (T40I), ORF8 (del119/120) and N (D63G, R203M, G215C, D377Y) to the increasing speculation about its ability to escape immune response, has been a major concern for the ongoing vaccination programs 8 11 . Besides this, IgG response was also assessed using whole inactivated SARS-CoV-2 antigen, nucleocapsid and S1-RBD protein IgG ELISA. inactivated SARS-CoV-2, S1-RBD protein and N protein respectively (Figure 1h-j) .

A significant increase in the NAb titer against B.1 variant in recovered cases with vaccination and breakthrough cases was observed compared to the Covid-19 naive vaccinees. 6 Similarly, a significant increase in NAb titer was also observed among these two groups against 

PDY contributed to study design, data analysis, interpretation and writing. RRS, GS, GRD, DAN, AMS, DYP and SKY contributed to data collection, data analysis, interpretation and writing. PA, NG, SP, and BB contributed to the critical review and finalization of the paper.

Authors do not have a conflict of interest among themselves.

The 

Clinical characterization and Genomic analysis of COVID-19 breakthrough infections during second wave in different states of India. medRxiv 2021

PANGO lineages

Resurgence of SARS-CoV-2 in India: Potential role of the B. 1.617. 2 (Delta) variant and delayed interventions. medRxiv

Effectiveness of COVID-19 vaccines against the B. 1.617. 2 variant. medRxiv

Neutralization against B. 1.351 and B. 1.617. 2 with sera of COVID-19 recovered cases and vaccinees of BBV152. bioRxiv

Neutralization of Delta variant with sera of Covishield vaccinees and COVID-19 recovered vaccinated individuals

PANGO lineages

Vaccine breakthrough infections with SARS-CoV-2 variants

Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report. medRxiv

Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. The Indian journal of medical research